Tillgänglig läkemedelsinformation i Sverige
Kontakta ossFAQ

L04AC16 - Guselkumab

  1. L01Antineoplastiska medel

  2. L02Endokrinterapi

  3. L03Immunstimulerande medel

  4. L04Immunsuppressiva medel

  1. L04AImmunsuppressiva medel

  1. L04AASelektiva immunsuppressiva medel

  2. L04ABTumörnekrosfaktor alfa (TNF-) hämmare

  3. L04ACInterleukinhämmare

  4. L04ADKalcineurinhämmare

  5. L04AESfingosin-1-fosfat (S1P) receptormodulatorer

  6. L04AFJanus-associerat kinas (JAK) hämmare

  7. L04AGMonoklonala antikroppar

  8. L04AHMammalian target of rapamycin (mTOR) kinashämmare

  9. L04AJKomplementhämmare

  10. L04AKDihydroorotatdehydrogenas (DHODH) hämmare

  11. L04ALNeonatal Fc-receptor (FcRn) hämmare

  12. L04AXÖvriga immunsuppressiva medel

  1. L04AC01Daklizumab

  2. L04AC02Basiliximab

  3. L04AC03Anakinra

  4. L04AC04Rilonacept

  5. L04AC05Ustekinumab

  6. L04AC07Tocilizumab

  7. L04AC08Kanakinumab

  8. L04AC09Briakinumab

  9. L04AC10Sekukinumab

  10. L04AC11Siltuximab

  11. L04AC12Brodalumab

  12. L04AC13Ixekizumab

  13. L04AC14Sarilumab

  14. L04AC15Sirukumab

  15. L04AC16Guselkumab

  16. L04AC17Tildrakizumab

  17. L04AC18Risankizumab

  18. L04AC19Satralizumab

  19. L04AC20Netakimab

  20. L04AC21Bimekizumab

  21. L04AC22Spesolimab

  22. L04AC23Olokizumab

  23. L04AC24Mirikizumab

  24. L04AC25Levilimab

  25. L04AC26Goflikicept